Long-term Outcomes and Biomarker Correlates of a Multi-institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver Tumors
PURPOSE: To evaluate long-term outcomes and determine whether longitudinal plasma profiling provides biological insight into disease progression after proton hypofractionated ablative radiation therapy (HART) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). PATIENTS AND METHODS: In this single-arm, multi-institutional phase II trial, 92 patients with localized unresectable HCC or ICC with Child-Pugh class A/B liver function received HART (up to 67.5 GyE in 15 fractions). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Plasma samples were collected at baseline, days 1, 8, 15, and 1-month after treatment for exploratory correlative analyses. RESULTS: Among evaluable patients (44 HCC, 39 ICC), median OS was 29.2 months (HCC) and 20.8 months (ICC), with 5-year OS rates of 25.9% and 12.3%, respectively. Median PFS was 13.8 months (HCC) and 8.4 months (ICC). In-field local failure occurred in 2 HCC (4.5%) and 7 ICC (17.9%) patients, whereas out-of-field intrahepatic/distant progression remained the predominant pattern of failure. No grade >3 treatment-related toxicities were observed. Exploratory plasma profiling identified distinct biological signatures associated with progression: HCC was characterized by markers of hypoxia, inflammation, vascular remodeling, stromal activation, and hepatic regeneration, whereas associations in ICC predominantly involved signatures of hypoxia and vascular remodeling. CONCLUSIONS: HART provides durable long-term in-field local control with minimal toxicity, but disease progression remains predominantly out-of-field intrahepatic/distant. Exploratory correlative analyses suggest that biological signatures reflecting vascular remodeling, hypoxia, inflammation, stromal activation, and hepatic reserve are associated with progression despite successful local therapy, informing future translational studies and combination strategies.
Authors
- Zoe Guan (ORCID: https://orcid.org/0000-0002-1015-4666)
- Christopher H. Crane (ORCID: https://orcid.org/0000-0001-5143-2784)
- Joseph Wang Franses (ORCID: https://orcid.org/0000-0002-2517-4950)
- Leilana Ly (ORCID: https://orcid.org/0009-0006-3192-7812)
- Thomas F. DeLaney (ORCID: https://orcid.org/0000-0002-0346-3487)
- Dan Gabriel Duda (ORCID: https://orcid.org/0000-0001-7065-8797)
- Eugene Jon Koay (ORCID: https://orcid.org/0000-0001-7675-3461)
- Kenneth K. Tanabe (ORCID: https://orcid.org/0000-0003-1920-3417)
- Theodore Sunki Hong (ORCID: https://orcid.org/0000-0001-8481-6581)
- Lipika Goyal (ORCID: https://orcid.org/0000-0002-9777-6221)
- Edgar Ben‐Josef (ORCID: https://orcid.org/0000-0003-1292-9565)
- Cristina Rosa Ferrone (ORCID: https://orcid.org/0000-0002-6295-1085)
- David P. Ryan (ORCID: https://orcid.org/0000-0002-9685-673X)
- Jennifer Yon-Li Wo (ORCID: https://orcid.org/0000-0001-9872-5912)
- Hannah Johnson Roberts (ORCID: https://orcid.org/0000-0003-2110-9542)
- Jeffrey William Clark (ORCID: https://orcid.org/0000-0001-9524-3600)
- Andrew Xiuxuan Zhu (ORCID: https://orcid.org/0000-0003-4873-5033)
- Jill N. Allen (ORCID: https://orcid.org/0000-0002-1446-2981)
- Lorraine C. Drapek (ORCID: https://orcid.org/0009-0000-3154-1078)
- Beow Yong Yeap (ORCID: https://orcid.org/0009-0004-6157-5489)
Institutions
- Cedars-Sinai Medical Center (US)
- Dartmouth–Hitchcock Medical Center (US)
- Houston Methodist (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Palo Alto University (US)
- Somerville Hospital (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- Massachusetts General Hospital (US)
- Methodist Hospital (US)
- Dana-Farber Cancer Institute (US)
- Stanford Medicine (US)
- University of Pennsylvania (US)
- Philadelphia University (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-1848
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute
- Department of Defense Education Activity